Evidence for Disruption of Mg(2+) Pair as a Resistance Mechanism Against HIV-1 Integrase Strand Transfer Inhibitors.
PMID: 32974383
2020
Frontiers in molecular biosciences
Introduction: There are three commonly frequent resistance pathways among the resistance mutations: N155H, Q148HRK, and Y143HC; interestingly, N155H and Q148HRK are mutually exclusive.
Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
PMID: 31037930
2019
Revista espanola de quimioterapia
Introduction: Different pathways against first-generation InSTIs were identified whose primary mutations include the substitutions N155H, Q148K/R/H, and Y143R/C.
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Abstract: The most frequent INSTI resistance mutation was N155H, followed by Q148H/K/R, G140A/C/S, E138A/K/T and Y143C/H/R.
Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance.
PMID: 30648124
2019
Open forum infectious diseases
Introduction: DTG appears to have a high genetic barrier to resistance, unlike the other drugs within the INSTI class, raltegravir and elvitegravir, which select for major resistance mutations such as N155H, Y143H/R/C, G140A/S, and Q148H/R/K.
Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain.
PMID: 30753573
2019
The Journal of antimicrobial chemotherapy
Abstract: INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1).
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
PMID: 31430369
2019
The Journal of antimicrobial chemotherapy
Method: Primary INSTI resistance (-R) substitutions were T66I/A/K, E92Q/G, T97A, F121Y, Y143R/H/C, S147G, Q148H/K/R, N155H/S and R263K in IN.
Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence.
Result: Curiously, four isolates showed mutations related to more than one of the three main resistance pathways: two from Italy, one with both N155H and Y143R and another with Q148H and Y143H; one from Canada with N155H and Y143C; and one from France with N155H and Q148R.
Result: This is in agreement with the fact that resistance pathways are mutually exclusive, and the N155H pathway is more likely to be further converted into the Q148HKR variants than into Y143CRH.
Result: This observation highlights the fact that T97A does not play a rol
Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa.
PMID: 29462322
2018
The Journal of antimicrobial chemotherapy
Abstract: Major INSTI resistance mutations were detected only at <20% threshold, at a prevalence of 2.4% (2.5% in subtype A, 2.4% C, 0% D, 8.3% G and 2.4% in recombinants) and included T66A/I (0.7%), E92G (0.5%), Y143C/S (0.7%), S147G (0.2%) and Q148R (0.5%).
Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.
PMID: 29631420
2018
AIDS research and human retroviruses
Abstract: Among them, 10 harbored N155H, 4 Q148H, 2 Q148R, 2 Y143C/S, and 2 T66A/I/T, respectively.
Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
Introduction: Resistance is commonly associated with selection of one of the signature raltegravir resistance mutations Y143C/R/H, Q148H/K/R or N155H.
Result: 2), including T97A and Y143C (both 0.2%).
Result: In a sample taken 28 days later, 77.5% of the population contained N155H, 15.4% had T97A and variants with Y143C were not detected anymore.
Result: In the subsequent sample 70 days after start of raltegravir therapy, N155H had increased to 88.6% and Y143C had reappeared in 11.8% of the reads.
Result: Interestingly, in the two other cultures, N155H emerge
HIV mutation literature information.
PMID: 
2020
Frontiers in molecular biosciences
Browser Board
Co-occurred Entities
Filtrator
ViMRT